Scalper1 News
Biotech Sarepta Therapeutics (SRPT) said Monday that the FDA sent it detailed guidelines for testing its muscular-dystrophy drug after a previous rejection, leading Sarepta to believe it can file for approval again by the end of the year. Sarepta’s stock was up nearly 50% in midday trading on the stock market today, near 36, a five-month high. Last year, Sarepta attempted to win accelerated approval for the drug, eteplirsen, based on a study Scalper1 News
Scalper1 News